Loxoprofen is an anti-inflammatory drug that requires bioactivation into the trans-OH metabolite to exert pharmacological activity. Evidence suggests that carbonyl reduc- 
| INTRODUCTION
Loxoprofen is a nonsteroidal anti-inflammatory drug with analgesic and anti-pyretic properties (Naruto, Tanaka, Hayashi, & Terada, 1984; Tanaka, Nishikawa, & Hayashi, 1983; Tanaka, Nishikawa, Matsuda, Yamazaki, & Hayashi, 1984) . Loxoprofen was initially marketed as an oral drug, and a topical formulation is also available and has been widely used in Japan since 2006 (Loxonin® gel 1%, Daiichi Sankyo Co., Ltd, Tokyo, Japan) Sawamura, Kazui, Kurihara, & Izumi, 2015) . Loxoprofen is a prodrug that undergoes enzymatic reduction into the pharmacologically active trans-OH metabolite. The trans-OH metabolite of loxoprofen, not the parent drug or the cis-OH isomer, is a strong and non-selective inhibitor of pro-inflammatory cyclooxygenase 2 (COX-2) (Riendeau et al., 2004; Sugimoto, Kojima, Asami, Iizuka, & Matsuda, 1991 ). An early report by Ohara et al. noted that the bioactivation of loxoprofen is catalysed by hepatic carbonyl reductases (CBRs) (Ohara, Miyabe, Deyashiki, Matsuura, & Hara, 1995) . More recently, Sawamura et al. showed that carbonyl reductase 1 (CBR1) is the predominant enzyme involved in the formation of the trans-OH metabolite in human skin.
The immunodepletion of CBR1 in skin homogenates decreased the reduction of loxoprofen to its trans-OH form by more than 80% (Sawamura, Sakurai, et al., 2015) .
CBR1 is a cytosolic NADPH dependent enzyme that catalyses the reduction of endogenous and exogenous carbonyl substrates (Malatkova, Maser, & Wsol, 2010; Shi & Di, 2017) . Evidence suggests that genetic polymorphisms in CBR1 impact the metabolism of carbonyl substrates (Shi & Di, 2017) . A functional single nucleotide polymorphism (SNP) in the 3′-untranslated region of CBR1 (rs9024, G > A) impacts CBR1 expression in liver and myocardium through mechanisms involving the binding of specific microRNAs to the polymorphic site (Kalabus et al., 2012; Gonzalez-Covarrubias, Zhang, Kalabus, Relling, & Blanco, 2009 , Quinones-Lombrana et al., 2014 . Liver cytosols with CBR1 rs9024 homozygous GG genotypes showed higher maximal rates of doxorubicinol synthesis (1.5-fold) compared with samples with heterozygous GA genotypes (Gonzalez-Covarrubias et al., 2009 Figure 1a .
Loxoprofen and NADPH stock solutions were prepared in 0.1 M potassium phosphate buffer (pH 7.4).
| Human liver samples
The 
| Human lymphoblastoid cell lines
Lymphoblastoid cell lines (GM10853, GM10845, GM10857, GM10858, GM10860, GM17240, GM16654, GM16688, and GM16689) derived from donors with European (n = 6) or Chinese (n = 3) ancestries were purchased from the Coriell Institute for Medical Research (Camden, NJ). Cultures were maintained in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum, 100 U/ml penicillin, and 100 μg/ml streptomycin (Thermo Fisher Scientific, Waltham, MA). Cultures were grown using standard incubation conditions at 37°C, 5% CO 2 , and 95% relative humidity. Figure 1c) . On average, the synthesis ratios of trans-OH/ cis-OH forms of loxoprofen were 33% higher in liver cytosols from donors homozygous for the CBR1 rs9024 GG allele in comparison to the ratios in samples from donors with heterozygous GA genotypes (CBR1 rs9024 GG mole of trans-OH form/mole of cis-OH form : 4.85 ± 1.49 vs.
| Quantification of trans-and cis-OH forms of loxoprofen

| Statistical analysis
CBR1 rs9024 GA mole of trans-OH form/mole of cis-OH form : 3.66 ± 1.23.
Student's t-test p = 0.044. Figure 1d ). Pearson's correlation analysis showed no linear correlation between the CBR1 protein content and the trans-OH/cis-OH loxoprofen ratios (r p = 0.258, p = 0.224). The reason for this discrepancy is unclear. It is known that CBR1 is subjected to posttranslational modifications, e.g. S-glutathionylation in cysteine 226, that impact catalytic activity towards specific substrates (Hartmanova et al., 2013) . Thus, studies with more robust sample sizes coupled to protein content analysis of CBR1 isoforms are needed to further define the contribution of CBR1 expression to the synthesis of relevant metabolites such as trans-OH loxoprofen in human liver. .405. Figure 1e ). authors concluded that the extrahepatic metabolism of loxoprofen by blood cells could be of pharmacological relevance irrespective of the route of administration (Koo et al., 2005; Sawamura, Sakurai, et al., 2015) . This study provides a foundation to investigate the contribution of CBR1 rs9024 to the pharmacokinetics and pharmacodynamics of loxoprofen in humans.
